Safety of medium- to long-term glucocorticoid therapy in rheumatoid arthritis: A meta-analysis

Rheumatology

Volumn 48, Issue 7, 2009, Pages 807-811

  Ravindran, Vinod ^a   Rachapalli, Satish ^a   Choy, Ernest H ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Glucocorticoid; Meta analysis; Rheumatoid arthritis; Treatment

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; GLUCOCORTICOID; METHYLPREDNISOLONE ACETATE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PREDNISOLONE; SALAZOSULFAPYRIDINE;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE DURATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; HUMAN; LONG TERM CARE; LOW DRUG DOSE; META ANALYSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; SENSITIVITY ANALYSIS; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ARTHRITIS, RHEUMATOID; GLUCOCORTICOIDS; HUMANS; ODDS RATIO; PREDNISOLONE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SAFETY; TREATMENT OUTCOME;

EID: 67650073256     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kep096     Document Type: Article

References (54)

1. Gotzsche PC, Johansen HK. Short term low dose corticosteroids vs. placebo and non-steroidal anti-inflammatory drugs in rheumatoid arthritis. Cochrane Database Syst Rev 2005;(1):CD000189.
2. Criswell LA, Robinson VA, Saag KKS et al. Moderate-term, low-dose corticosteroids for rheumatoid arthritis. Cochrane Database Syst Rev 1998;(3):CD001158.
3. Kirwan JR, Bijlsma JWJ, Boers M, Shea BJ. Effects of glucocorticoids on radiological progression in rheumatoid arthritis. Cochrane Database Syst Rev 2007;(1):CD006356.
4. Hoes JN, Jacobs JWG, Boers M et al. EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis 2007;66:1560-7.
5. Felson DT, Anderson JJ, Boers M et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-35.
6. Prevoo MLL, Van 'T Hof MA, Kuper HH, Van Leeuwen MA, Van De Putte LBA, Van Riel PLCM. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-8.
7. Begg C, Cho M, Eastwood S et al. Improving the quality of reporting of randomised controlled trials. The CONSORT statement. J Am Med Assoc 1996;276:637-9.
8. Choy EHS, Smith C, Dore' CJ, Scott DL. A meta-analysis of the efficacy and toxicity of combining disease-modifying anti-rheumatic drugs in rheumatoid arthritis based on patient withdrawal. Rheumatology 2005;44:1414-21.
9. Ravindran V, Scott DL, Choy EHS. A systematic review and meta-analysis of efficacy and toxicity of disease modifying anti-rheumatic drugs and biologic agents for psoriatic arthritis. Ann Rheum 2008;67:855-9.
10. Jadad AR, Moore RA, Carroll D et al. Assessing the quality of reports of randomized controlled trials: Is blinding necessary? Control Clin Trials 1996;17:1-12.
11. ICH Harmonised Tripartite Guideline for Good Clinical Practice (ICH GCP). Geneva, Switzerland: ICH Secretariat, IFPMA, 1996.
12. Million R, Kellgren JH, Poole P, Jayson MIV. Long term study of management of rheumatoid arthritis. Lancet 1984;I:812-16.
13. Hansen M, Podenphant J, Florescu A et al. A randomised controlled trial of differentiated prednisolone treatment in active rheumatoid arthritis: Clinical benefits and skeletal side effects. Ann Rheum Dis 1999;58:713-18.
14. Svensson B, Boonen A, Albertsson K et al. Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: A two-year randomized trial. Arthritis Rheum 2005;52:3360-70.
15. Suponitskaia EV, Smirnov AV, Aleksandrova EN, Novikov AA, Nasonov EL. Effect of small-dose glucocorticoids on the course of early rheumatic arthritis. Klin Med (Mosk) 2004;82:39-42.
16. Joint Committee of the Medical Research Council and Nuffield Foundation on clinical trials of cortisone, ACTH and other therapeutic measures in chronic rheumatic diseases: A comparison of cortisone and aspirin in the treatment of early cases of rheumatoid arthritis. Br Med J 1954;1:1223-7.
17. Empire Rheumatism Council Sub Committee. Multicentre controlled trial comparing cortisone acetate and acetetyl salicylic acid in the long-term treatment of rheumatoid arthritis. Ann Rheum Dis 1955;14:353-63.
18. Joint Committee of the Medical Research Council and Nuffield Foundation on clinical trials of cortisone, ACTH and other therapeutic measures in chronic rheumatic diseases: A comparison of prednisolone with aspirin or other analgesics in the treatment of rheumatoid arthritis. Ann Rheum Dis 1959;18:173-87.
19. Gray R, Doherty SM, Galloway J, Coulton L, De Broe M, Kanis JA. A double-blind study of deflazacort and prednisone in patients with chronic inflammatory disorders. Arthritis Rheum 1991;34:287-95.
20. Messina OD, Barreira JC, Zanchetta JR et al. Effect of low doses of deflazacort vs. prednisone on bone mineral content in premenopausal rheumatoid arthritis. J Rheumatol 1992;19:1520-6.
21. Stenberg VI, FiechtnerJJ, Rice JR, Miller DR, Johnson LK. Endocrine control of inflammation: Rheumatoid arthritis double blind, crossover clinical trial. Int J Clin Pharmacol Res 1992;XII:11-18.
22. Van Schaardenburgh D, Valkema R, Dijkmans BAC et al. Prednisolone treatment in elderly onset rheumatoid arthritis: Disease activity and bone mass in comparison to treatment with chloroquine treatment. Arthritis Rheum 1995;38:334-42.
23. Boers M, Verhoeven AC, Markusse HM et al. Randomised comparison of combined step down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 1997;350:309-18.
24. Kirwan JR, Hallgren R, Mielants H et al. A randomised placebo controlled 12 weeks trial of budesonide and prednisolone in rheumatoid arthritis. Ann Rheum Dis 2004;63:688-95.
25. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 2005;52:3381-90.
26. De Andrade JR, McCormick NN, Hill AGS. Small doses of prednisolone in the management of rheumatoid arthritis. Ann Rheum Dis 1964;23:158-62.
27. Jick H, Pinals RS, Ullian R, Slone D, Muench H. Dexamethasone and dexamethasone-aspirin in the treatment of chronic rheumatoid arthritis. Lancet 1965;2:1203-5.
28. Boardmann P, Hart FD. Clinical measurement of the anti-inflammatory effects of salicylates in rheumatoid arthritis. Br Med J 1967;4:264-8.
29. Jasani MK, Downie WW, Samuels BM, Buchanan WW. Ibuprofen in rheumatoid arthritis. Ann Rheum Dis 1968;27:457-62.
30. Ritchie DM, Boyle JA, McInnes JM et al. Clinical studies with an articular index for the assessment of joint tenderness in patients with rheumatoid arthritis. Q J Med 1968;37:393-406.
31. Dick WC, Nuki G, Whaley K, Deodhar S, Buchanan WW. Some aspects in the quantitation of inflammation in joints of patients suffering from rheumatoid arthritis. Rheumatol Phys Med 1970;10(Suppl. 10):40-7.
32. Lee P, Webb J, Anderson JA, Buchanan WW. Method for assessing therapeutic potential of anti-inflammatory antirheumatic drugs in rheumatoid arthritis. Br Med J 1973;2:685-8.
33. Lee P, Jasani MK, Dick WC, Buchanan WW. Evaluation of a functional index in rheumatoid arthritis. Scand J Rheumatol 1973;2:71-7.
34. Deodhar SD, Dick WC, Hodgkinson R, Buchanan WW. Measurement of clinical response to anti-inflammatory drug therapy in rheumatoid arthritis. Q J Med 1973;166:387-401.
35. Webb J, Downie WW, Dick WC, Lee P. Evaluation of digital joint circumference measurements in rheumatoid arthritis. Scand J Rheumatol 1973;2:127-31.
36. Berry H, Huskisson EC. Isotopic indices as a measure of inflammation in rheumatoid arthritis. Ann Rheum Dis 1974;33:523-5.
37. Harris ED, Emkey RD, Nichols JE, Newberg A. Low dose prednisolone therapy in rheumatoid arthritis: A double blind study. J Rheumatol 1983;10:713-21.
38. Corkill MM, Kirkham BW, Chikanza IC, Gibson T, Panayi GS. Intramuscular depot methylprednisolone induction of chrysotherapy in rheumatoid arthritis: A 24-week randomized controlled trial. Br J Rheumatol 1990;29:274-9.
39. Choy EH, Kingsley GH, Corkill MM, Panayi GS. Intramuscular methylprednisolone is superior to pulse oral methylprednisolone during the induction phase of chrysotherapy. Br J Rheumatol 1993;32:734-9.
40. Van Gestel AM, Laan RFJM, Haagsma CJ, van der Putte LBA, van Riel PLCM. Low-dose oral steroids as bridge therapy in rheumatoid arthritis patients starting with parenteral gold: A randomised double blind placebo-controlled trial. Br J Rheumatol 1995;34:347-51.
41. Ciconelli RM, Ferraz MB, Vision RA, Oliveira LM, Atra E. A randomized double-blind controlled trial of sulphasalazine combined with pulses of methylprednisolone or placebo in the treatment of rheumatoid arthritis. Br J Rheumatol 1996;35:150-4.
42. Gerlag DM, Haringman JJ, Smeets TJM et al. Effects of oral prednisolone on biomarkers in synovial tissue and clinical improvement in rheumatoid arthritis. Arthritis Rheum 2004;50:3783-91.
43. Gough A, Sheeran T, Arthur V, Panayi G, Emery P. Adverse interaction between intramuscular methylprednisolone and sulphasalazine in patients with early rheumatoid arthritis. A pilot study. Scand J Rheumatol 1994;23:46-8.
44. Chamberlain MA, Keenan J. The effect of low dose of prednisolone compared with placebo on function and on the hypothalamic pituitary adrenal axis in patients with rheumatoid arthritis. Rheumatol Rehabil 1976;15:17-23.
45. Kirwan JR; Arthritis & Rheumatism Council Low Dose Glucocorticoid Study Group. The effect of glucocoticoids in the joint destruction in rheumatoid arthritis. N Engl J Med 1995;333:142-6.
46. van Everdingen AA, Jacobs JWG, Siewertsz van Reesema DR, Bijlsma WJ. Low dose prednisolone therapy for patients with early active rheumatoid arthritis: Clinical efficacy, disease-modifying properties, and side effects. Ann Intern Med 2002;136: 1-12.
47. Capell HA, Madhok R, Hunter JA et al. Lack of radiological and clinical benefit over two years of low dose prednisolone for rheumatoid arthritis: Results of a randomised controlled trial. Ann Rheum Dis 2004;63:797-803.
48. Choy EH, Kingsley GH, Khoshaba B, Ppipitone N, Scott DL; Methylprednisolone Study Group. A two-year randomised controlled trial of intramuscular depot steroids in patients with established rheumatoid arthritis who have shown an incomplete response to disease modifying antirheumatic drugs. Ann Rheum Dis 2005; 64:1288-93.
49. Wassenberg S, Rau R, Steinfeld P, Zeidler H; for the Low-Dose Prednisolone Therapy Study Group. Very low-dose prednisolone in early rheumatoid arthritis retards radiographic progression over two years: A multicenter, double blind, placebo-controlled trial. Arthritis Rheum 2005;52:3371-80.
50. Da Silva JA, Jacobs JW, Kirwan JR et al. Safety of low dose glucocorticoid treatment in rheumatoid arthritis: Published evidence and prospective trial data. Ann Rheum Dis 2006;65:285-93.
51. Buttgereit F, da Silva JAP, Boers M et al. Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: Current questions and tentative answers in rheumatology. Ann Rheum Dis 2002;61:718-22.
52. Borzak S, Ridker PM. Discordance between meta-analyses and large scale randomised, controlled trials. Ann Intern Med 1995;123:873-7.
53. Lassere MN, Johnson KR, Boers M et al. Standardized assessment of adverse events in rheumatology clinical trials: Summary of the OMERACT 7 drug safety module update. J Rheumatol 2005;32:2037-41.
54. Harris ED. Prednisolone in early rheumatoid arthritis: An antiinvasive effect. Arthritis Rheum 2005;52:3324-5.